Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer

被引：0
|
作者：
Bilgin, Burak [1 ]
Sendur, Mehmet A. N. [1 ]
Hizal, Mutlu [1 ]
Akinci, Muhammed Bulent [1 ]
Dede, Didem Sener [1 ]
Yalcin, Bulent [1 ]
机构：
[1] Yildirim Beyazit Univ, Dept Med Oncol, Ankara, Turkey
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 02期
关键词：
FULVESTRANT; 500; MG; DOUBLE-BLIND; THERAPY; PALBOCICLIB;
D O I：
10.2217/fon-2018-0086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：105 / 107
页数：3
相关论文
共 50 条
  • [41] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [42] Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
    Van Asten, Kathleen
    Slembrouck, Laurence
    Olbrecht, Siel
    Jongen, Lynn
    Brouckaert, Olivier
    Wildiers, Hans
    Floris, Giuseppe
    Van Limbergen, Erik
    Weltens, Caroline
    Smeets, Ann
    Paridaens, Robert
    Giobbie-Hurder, Anita
    Regan, Meredith M.
    Viale, Giuseppe
    Thurlimann, Beat
    Vergote, Ignace
    Christodoulou, Evangelia
    Van Calster, Ben
    Neven, Patrick
    ONCOLOGIST, 2019, 24 (02): : 165 - 171
  • [43] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
    Forstmeyer, D.
    ONKOLOGE, 2016, 22 (07): : 507 - 508
  • [44] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Hugo Herrscher
    Michel Velten
    Julie Leblanc
    Michal Kalish-Weindling
    Cathie Fischbach
    Delphine Exinger
    Xavier Pivot
    Thierry Petit
    Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
  • [46] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [47] Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer
    Ferro, Antonella
    Campora, Michela
    Caldara, Alessia
    De Lisi, Delia
    Lorenzi, Martina
    Monteverdi, Sara
    Mihai, Raluca
    Bisio, Alessandra
    Dipasquale, Mariachiara
    Caffo, Orazio
    Ciribilli, Yari
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (12)
  • [48] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [49] Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
    Konecny, G
    Pauletti, G
    Pegram, M
    Untch, M
    Dandekar, S
    Aguilar, Z
    Wilson, C
    Rong, HM
    Bauerfeind, I
    Felber, M
    Wang, HJ
    Beryt, M
    Seshadri, R
    Hepp, H
    Slamon, DJ
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (02) : 142 - 153
  • [50] Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
    Tommasi, Chiara
    Airo, Giulia
    Prattico, Fabiana
    Testi, Irene
    Coriano, Matilde
    Pellegrino, Benedetta
    Denaro, Nerina
    Demurtas, Laura
    Dessi, Mariele
    Murgia, Sara
    Mura, Giovanni
    Wekking, Demi
    Scartozzi, Mario
    Musolino, Antonino
    Solinas, Cinzia
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
12345